Clinical analysis of unclassifiable B-cell lymphoma intermediates between diffuse lage B-cell lymphoma and Burkitt lymphoma
10.3969/j.issn.1000-8179.2016.03.336
- VernacularTitle:介于弥漫大B细胞淋巴瘤和伯基特淋巴瘤之间的未分类淋巴瘤
- Author:
Sucai LI
;
Feifei NAN
;
Sisi JIA
;
Jingyu CAO
;
Shanshan FAN
;
Chao ZHANG
;
Mingzhi ZHANG
;
Lei ZHANG
- Publication Type:Journal Article
- Keywords:
unclassifiable B-cell lymphoma;
diffuse large B-cell lymphoma;
Burkitt lymphoma;
gray zone lymphoma;
c-myc;
Bcl-2
- From:
Chinese Journal of Clinical Oncology
2016;(3):105-110
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze clinical characteristics, treatment, and prognosis of B-cell lymphoma, unclassifiable, with features in-termediate between diffuse large B-cell lymphoma and Burkitt lymphoma (DLBCL/BL). Methods:The clinical and pathological data of 13 DLBCL/BL patients, who were treated in the First Affiliated Hospital of Zhengzhou University between January 2013 and December 2014, were collected. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Through the log-rank test, survival curves were compared among groups classified by clinical stage, age, serum lactate dehydrogenase (LDH) lev-el, international prognostic index (IPI) score, or first chemotherapy regimen. Results:Among the 13 patients with DLBCL/BL, 12 pa-tients showed extra-nodal involvement. The median OS and PFS were only 10 and 6 months, respectively. Univariate analysis showed that the LDH levels and IPI scores exerted statistically significant effects on prognosis. Some borderline differences in survival were not-ed among the CHOP, CHOP-like, and intensive chemotherapy groups. Conclusion:DLBCL/BL is an aggressive B-cell lymphoma with a short survival time. The majority of patients presented extra-nodal involvement. DLBCL/BL did not respond well to CHOP or CHOP-like regimen, and more intensive chemotherapy may improve survival. Elevated LDH levels and high IPI scores were predictors of poor sur-vival.
